Trial reportBehaviour research and therapy2025
Mobile intervention to address cannabis use disorder among black adults: A proof-of-concept randomized controlled trial.
Trial report in Behaviour research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAfrican American or Black adults who use cannabis face significant cannabis-related health disparities, including more frequent cannabis use and higher rates of Cannabis Use Disorder (CUD) relative to non-Hispanic/Latinx White adults who use cannabis. This highlights the need for accessible, culturally tailored interventions that address the unique needs of Black adults with CUD. This study evaluated the feasibility, utilization, acceptability, and initial efficacy of a culturally tailored mobile intervention (Culturally Tailored-Mobile Integrated Cannabis and Anxiety Reduction Treatment [CT-MICART]), integrating false safety behavior (FSB) reduction or elimination skills with use reduction or cessation skills.
methodsParticipants (N = 50, 50.0% female, M
resultsResults indicated strong feasibility, high utilization, and positive acceptability. Participants in the CT-MICART + EMA group demonstrated statistically significantly lower cannabis use frequency rates and less time spent intoxicated from cannabis compared to the EMA-only group. No significant effects were observed for cannabis-related problems, CUD severity, or FSB use at the 6-week follow-up.
conclusionThis study provides initial evidence for the feasibility, acceptability, and efficacy of CT-MICART + EMA for certain cannabis use processes among Black adults with probable CUD. Larger trials are necessary to test whether CT-MICART holds potential as a scalable solution to support use reduction or cessation goals for this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.